Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02094833
Other study ID # A3L31
Secondary ID U1111-1127-6896
Status Completed
Phase Phase 3
First received March 20, 2014
Last updated April 25, 2017
Start date March 2014
Est. completion date November 2016

Study information

Verified date April 2017
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate the immunogenicity and safety of a novel DTaP-IPV-Hep B-PRP~T fully liquid combined hexavalent vaccine (study vaccine) administered at 2, 4, and 6 months of age compared to Sanofi Pasteur's DTaP-IPV//PRP~T combined vaccine (Pentaxim™) given at 2, 4, and 6 months of age and Hep B vaccine (Euvax B®) given at 1 and 6 months of age in South Korean infants that received a birth dose of Hep B and born to mothers documented to be serum anti-HBs Ag negative.

Primary Objective

- To demonstrate the non-inferiority in terms of seroprotection (Diphtheria, Tetanus, poliovirus types 1, 2, and 3, PRP-T, Hep B) and vaccine response for pertussis antigens (pertussis toxoid [PT] and filamentous haemagglutinin [FHA]) of Group A versus Group B, one month after the third dose of combined vaccines.

Secondary Objectives:

- To further study the immunogenicity of the two vaccination schemes, before the first dose and one month after the last dose of vaccines.

- To study the safety after each and any dose of vaccines administered in the two vaccination schemes


Description:

Study participants who received a first dose of recombinant Hep B vaccine at birth will receive either DTaP-IPV-Hep B-PRP~T combined vaccine at 2, 4, and 6 months of age + 3 doses of Hep B vaccine or Hep B vaccine (Euvax B®) at 1 and 6 months of age and DTaP IPV//PRP~T combined vaccine (Pentaxim™) at 2, 4, and 6 months of age, according to the official vaccination schedule for Hep B, DTaP, poliovirus, and Hib vaccinations in South Korea.


Recruitment information / eligibility

Status Completed
Enrollment 310
Est. completion date November 2016
Est. primary completion date April 2016
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 1 Month to 6 Months
Eligibility Inclusion Criteria:

- Aged 30 to 40 days on the day of the first study visit

- Born at full term of pregnancy (= 37 weeks) and with a birth weight = 2.5 kg

- Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative

- Participant and parent/legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures

- Born to known hepatitis B surface antigen (HBsAg) seronegative mother (documented laboratory result of HBsAg assay from the maternal blood sample is available)

- Have received one documented dose of Hep B vaccine at birth according to the national recommendations.

Exclusion Criteria:

- Participation in the 4 weeks preceding the trial inclusion or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure

- Receipt of any vaccine in the 4 weeks preceding any trial vaccination (except Bacille Calmette Guerin (BCG) vaccine) or planned receipt of any vaccine in the 8 days following any trial vaccination

- Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B (except the dose of Hep B vaccine given at birth) diseases or Haemophilus influenzae type b infection with either the trial vaccine or another vaccine

- Past or current receipt of immune globulins, blood or blood-derived products or planned administration during the trial

- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, since birth; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks since birth)

- Known personal or maternal history of Human Immunodeficiency Virus (HIV) or hepatitis C seropositivity

- History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, or Haemophilus influenzae type b infection, confirmed either clinically, serologically, or microbiologically

- Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances

- Known thrombocytopenia, as reported by the parent/legally acceptable representative

- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination

- In an emergency setting, or hospitalized involuntarily

- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion

- Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature = 38.0°C). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided

- Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study

- History of seizures.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
DTaP-IPV-Hep B-PRP~T combined vaccine
0.5 mL, Intramuscular
DTaP-IPV//PRP~T and Hepatitis B vaccine
0.5 mL, Intramuscular

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Sanofi Pasteur, a Sanofi Company

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with anti-Diphtheria antibody concentrations = 0.01 International Units (IU)/mL Anti-Diphtheria antibodies will be measured by a toxin neutralization test 1 month post third vaccination
Primary Number of participants with anti-Tetanus antibody concentrations = 0.1 International unit (IU)/mL Anti-Tetanus antibodies will be measured by enzyme-linked immunosorbent assay (ELISA). 1 month post third vaccination
Primary Number of participants with = 4 fold increase in anti-PT and anti-FHA antibody concentrations (EU/mL) from 1 month pre-dose 1 to 1 month post-dose 3 Anti-PT and anti-FHA antibodies will be measured by enzyme-linked immunosorbent assay (ELISA). I month post dose 3
Secondary Number of participants with anti-Diphtheria antibody concentrations = 0.01 IU/mL and = 0.1 IU/mL International Units (IU)/mL Anti-Diphtheria antibodies will be measured by a toxin neutralization test Day 0 Pre-vaccination
Secondary Number of participants with anti-Hepatitis B antibody concentrations = 10 mIU/mL international unit (IU)/mL Anti-Hepatitis B antibodies will be measured by the commercially available VITROS ECi/ECiQ Immunodiagnostic System using chemiluminescence detection technology Day 0 Pre-vaccination
Secondary Number of participants with anti Diphtheria antibody concentrations = 0.1 IU/mL International Units (IU)/mL Anti-Diphtheria antibodies will be measured by a toxin neutralization test 1 month post third vaccination
Secondary Number of participants reporting solicited injection site and solicited systemic reactions, unsolicited adverse events, and serious adverse events following vaccination with either DTaP-IPV-Hep B-PRP~T combined vaccine or Pentaxim™ and Euvax B® vaccine Solicited injection site reactions Tenderness, Erythema, and Swelling. Solicited systemic reactions Fever (temperature), Vomiting, Crying abnormal, Drowsiness, Appetite loss, and Irritability. Day 0 and up to Day 180 post-vaccination
Secondary Number of participants with response to vaccine Pertussis toxoid (PT) and Filamentous Haemagglutinin (FHA) antigens Vaccine response defined as: Post-dose 3 anti-PT and anti-FHA antibody concentrations in ELISA units (EU)/mL = 4 x Lower Limit of Quantitation (LLOQ) if pre-vaccination concentration is < 4 x LLOQ or = pre-vaccination concentration if pre-vaccination concentrations = 4 x LLOQ 1 month post third vaccination
See also
  Status Clinical Trial Phase
Completed NCT01182311 - Duration of Long-term Immunity After Hepatitis B Virus Immunization
Completed NCT04971928 - Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment Phase 1
Completed NCT03285620 - A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants Phase 1
Completed NCT01884415 - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis Phase 3
Recruiting NCT05404919 - Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates Phase 2
Completed NCT02153320 - Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers Phase 1
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Completed NCT03567382 - Arresting Vertical Transmission of Hepatitis B Virus Phase 4
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Not yet recruiting NCT03604016 - Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Terminated NCT02604199 - A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection Phase 2
Completed NCT02540538 - Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders Phase 1
Completed NCT02169674 - Hepatitis B Booster Study in Adolescence Phase 4
Completed NCT02421666 - A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV N/A
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT01732354 - Study for Consolidation Period of Chronic Hepatitis B
Completed NCT01368497 - Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection Phase 3
Recruiting NCT01462981 - Cohort of Hepatitis B Research of Amsterdam N/A

External Links